Search

Breast Cancer Clinical Trials In Oklahoma

A Phase I/II Study of HKI-272 in Combination With Paclitaxel in Subjects With Advanced Solid Tumors
A Study of the Continued Efficacy and Safety of Zoledronic Acid in Patients With Documented Bone Met
A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previ
A Trial of Taxol and Bevacizumab vs. Gemcitabine, Taxol, and Bevacizumab in Advanced Breast Cancer
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment
Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who
Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Bre
Combination Chemotherapy in Treating Women With Breast Cancer
Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for S
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer
ErbB2 Over-Expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cance
Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Br
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surger
Letrozole After Tamoxifen in Treating Women With Breast Cancer
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Po
Prayer as a Possible Adjuvant Treatment for Breast Cancer
Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Rec
Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance
Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Bre
Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients Wi
Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-Positive (E
Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prosta
Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in
Treatment Decision Making Based on Blood Levels of Tumor Cells in Women With Metastatic Breast Cance
Weekly vs. Every 2 Week vs. Every 3 Week Administration of Abraxane/Bevacizumab Combination in Metas
Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surger
Zoledronate, Clodronate, or Ibandronate in Treating Women Who Have Undergone Surgery for Stage I, St

Comprehensive Cancer Control Plan

The Cherokee Nation Comprehensive Cancer Control (CNCCC) Project assists in the development of networks and collaboration that produce an infrastructure for a comprehensive approach to cancer within the Cherokee Nation. Since 2003, coalition members and partners have come together to discuss the burden of cancer in Cherokee Nation. Coalition members and partners include local, regional, state and national representatives committed to identifying areas of cancer concern, planning interventions, prioritizing greatest areas of identified need, and then implementing identified strategies and/or providing needed resources. This is the second edition of the Cherokee Nation Comprehensive Cancer Control Plan and will serve, like the first, as an information resource for health care professionals and community members, as well as a tool for the Cherokee Nation Comprehensive Cancer Control Coalition and its respective entities. The coalition is committed to the process of enhancing infrastructure for comprehensive cancer control in the Cherokee Nation with the ultimate goal of reducing morbidity and mortality amongĀ the Cherokee community.